 randomized trial cisplatin-containing treatments patients metastatic non-small-cell lung cancer Southwest Oncology Group study Six assessable patients measureable stage III non-small-cell lung cancer NSCLC treatment arms cisplatin methylglyoxal bisguanylhydrazone MGBG PVp PVpM cisplatin vinblastine PVe vinblastine mitomycin PVeMi vincristine mitomycin/cyclophosphamide doxorubicin cisplatin FOMi/CAP overall response rate complete responses partial remissions duration responses different treatment regimen months months overall median survival patients months different treatment Toxicity PVpM similarity results response duration response survival superiority platinum-based regimens standard clinical usage